Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft - No benefit of combination therapy

International Journal of Colorectal Disease

Volumn 28, Issue 3, 2013, Pages 385-398

  Wehler, Thomas C ^a   Hamdi, Swaantje ^a   Maderer, Annett ^a   Graf, Claudine ^a   Gockel, Ines ^a   Schmidtmann, Irene ^a   Hainz, Michael ^a   Berger, Martin R ^b   Theobald, Matthias ^a   Galle, Peter R ^a   Moehler, Markus ^a   Schimanski, Carl C ^a,c  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Marien Hospital Darmstadt   (Germany)

Author keywords

Colorectal cancer; Sorafenib; TKI

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 6; CASPASE 8; CASPASE 9; FLUOROURACIL; GADD45 BETA PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; IRINOTECAN; K RAS PROTEIN; KI 67 ANTIGEN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL ASSAY; CELL MIGRATION; CELL STRAIN CACO 2; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; MICE; MICE, SCID; NIACINAMIDE; PHENYLUREA COMPOUNDS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879463299     PISSN: 01791958     EISSN: 14321262     Source Type: Journal    
DOI: 10.1007/s00384-012-1551-2     Document Type: Article

References (34)

1. Greenlee RT, Murray T, Bolden S, Wingo PA et al (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7-33 (Pubitemid 30072093)
2. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK (2003) Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95:1276-1299 (Pubitemid 37160862)
3. August DA, Ottow RT, Sugarbaker PH (1984) Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev 3:303-324
4. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28(31):4697-7705
5. Sobrero A, Ackland S, Clarke S, Perez-Carrion R, Chiara S, Gapski J, Mainwaring P, Langer B, Young S (2009) Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 77:113-119
6. Welch S, Spithoff K, Rumble RB, Maroun J (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21(6):1152-1162
7. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767 (Pubitemid 20185636)
8. Cho KR, Vogelstein B (1992) Genetic alterations in the adenoma-carcinoma sequence. Cancer 70:1727-1731
9. Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9:138-141 (Pubitemid 23098782)
10. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237 (Pubitemid 47325606)
11. Li E, Hristova K (2006) Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. Biochemistry 45:6241-6251 (Pubitemid 43787791)
12. Mobius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, Jutting U, Siewert JR (2003) The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 29:890-894 (Pubitemid 37493289)
13. Liu XE, Sun XD, Wu JM (2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol 10:352-355
14. Yonemura Y, Endo Y, Tabata K, Kawamura T, Yun HY, Bandou E, Sasaki T, Miura M (2005) Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer. Int J Clin Oncol 10:318-327 (Pubitemid 41507205)
15. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM (1996) Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 2:1679-1684 (Pubitemid 26356351)
16. Wang KL, Wu TT, Choi IS, Wang H, Reseetkova E, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT (2007) Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Cancer 109:658-667 (Pubitemid 46233226)
17. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
18. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312-3318
19. Mross K, Steinbild S, Baas F, Gmehling D, Radtke M, Voliotis D, Brendel E, Christensen O, Unger C (2007) Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43:55-63 (Pubitemid 46054474)
20. Kupsch P, Henning BF, Passarge K, Richly H, Wiesemann K, Hilger RA, Scheulen ME, Christensen O, Brendel E, Schwartz B, Hofstra E, Voigtmann R et al (2005) Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 5:188-196
21. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE et al (2007) Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 25:4793-4799 (Pubitemid 350086483)
22. Cuteem EV, Sobrero AF, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T et al (2012) Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). J Clin Oncol 30(suppl; abstr 3502)
23. Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, Seeber S, Strumberg D (2005) The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16:129-136 (Pubitemid 40250607)
24. Huang R, Chen XQ, Huang Y, Chen N, Zeng H (2010) The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl 12:527-534
25. Panka DJ, Wang W, Atkins MB, Mier JW (2006) The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66:1611-1619 (Pubitemid 43259945)
26. Yu C, Friday BB, Lai JP, Yang L, Sarkaria J, Kay NE, Carter CA, Roberts LR, Kaufmann SH, Adjei AA (2006) Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther 5:2378-2387 (Pubitemid 44530475)
27. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL (2010) Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 52:88-95
28. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587-597
29. Liebermann DA, Hoffman B (2002) Myeloid differentiation (MyD)/growth arrest DNA damage (GADD) genes in tumor suppression, immunity and inflammation. Leukemia 16:527-541 (Pubitemid 34449730)
30. Nemoto S, Finkel T (2002) Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 295:2450-2452 (Pubitemid 34270258)
31. Smith ML, Kontny HU, Bortnick R, Fornace AJ Jr (1997) The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp Cell Res 230:61-68 (Pubitemid 27187540)
32. Zhang W, Bae I, Krishnaraju K, Azam N, Fan W, Smith K, Hoffman B, Liebermann DA (1999) CR6: A third member in the MyD118 and Gadd45 gene family which functions in negative growth control. Oncogene 18:4899-4907 (Pubitemid 29425296)
33. Qiu W, David D, Zhou B, Chu PG, Zhang B, Wu M, Xiao J, Han T, Zhu Z, Wang T, Liu X, Lopez R et al (2003) Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma. Am J Pathol 162:1961-1974 (Pubitemid 36613053)
34. Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, Fan HH, Feng WC, Wang CT, Lin LI, Hsu C, Cheng AL (2010) Induction of DNA damage-inducible gene GADD45{beta} contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 70:9309-9318